The impact of type 2 diabetes on circulating adipokines in patients with metabolic syndrome

Obesity Facts

Volumn 5, Issue 2, 2012, Pages 270-276

  Schindler, Karin ^a   Vila, Greisa ^a   Hoppichler, Friedrich ^b,c   Lechleitner, Monika ^c,d   Luger, Anton ^a   Anderwald, Christian ^a   Hoefler, Jrgen ^b,c   Tomasec, Goran ^b,c   Kautzky Willer, Alexandra ^a   Ludvik, Bernhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c SIPCAN Save Your Life   (Austria)

^d Hospital Hochzirl   (Austria)

Author keywords

Adipokine; Diabetes; GDF15; Metabolic syndrome; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; CREATININE; GLUCOSE; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ORAL ANTIDIABETIC AGENT; RESISTIN; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASPIN; AUTACOID;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; MIDDLE AGED; RISK FACTOR;

ADIPOKINES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RISK FACTORS;

EID: 84861839592     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000338729     Document Type: Article

References (21)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Meigs JB: Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 2010; 33: 1865-1871.
3. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
4. Rasouli N, Kern PA: Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 suppl 1):S64-73.
5. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M: The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914.
6. Promintzer M, Krebs M, Todoric J, Luger A, Bischof MG, Nowotny P, Wagner O, Esterbauer H, Anderwald C: Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 2007; 92: 4306-4312.
7. Maedler K, Schulthess FT, Bielman C, Berney T, Bonny C, Prentki M, Donath MY, Roduit R: Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases. FASEB J 2008; 22: 1905-1913.
8. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S: Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375.
9. Fagerberg B, Kellis D, Bergstrom G, Behre CJ: Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: A prospective study in 64-year-old women. J Intern Med 2011; 269: 636-643.
10. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C: Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009; 150: 1688-1696.
11. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997; 94: 11514-11519.
12. Taddei S, Virdis A: Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander? Eur Heart J 2010; 31: 1168-1171.
13. Vila G, Riedl M, Anderwald C, Resl M, Handisurya A, Clodi M, Prager G, Ludvik B, Krebs M, Luger A: The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011; 57: 309-316.
14. Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G, Wagner O, Kautzky-Willer A, Ludvik B, Clodi M, Luger A: Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab 2008; 93: 2307-2312.
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
16. ADA: Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31(suppl 1):S55-60.
17. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P: Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 2010; 33: 1567-1572.
18. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC: Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30: 2346-2353.
19. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ: Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
20. Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, Ludvik B: Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes Metab 2007; 9: 761-763.
21. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K: Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548.